Posted On: 10/08/2015 11:02:28 PM
Post# of 30079
The news today needs to be digested and likely the reason AMBS put it out a day ahead of time. This data goes back not a year or two, but back 13 years . When do you ever have real data, on humans, going back that far on a phase 2. It shows that the product works, is safe and no long-term effects. Basically says it all above the PR in the two bullet points.
This is what I wanted to see. It's was the obvious question. If people were treated over a wide time span, where are they now and how is the skin holding up. This is the nice thing about the upcoming ESS trial. The company doesn't have to wait years to see the outcome.
Amarantus Reports Preliminary 13-Year Longitudinal Follow-Up Human Patient Data for Engineered Skin Substitute Treatment of Congenital Giant Hairy Nevus
http://ir.amarantus.com/press-releases/detail...ngitudinal
Quote:
- Single ESS Treatment Provided Successful Skin Replacement on Infant Patient, Supporting Natural Skin Growth That Required no Additional Grafts or Reconstructive Surgery
- Data Provides Translational Support for Multiple Pediatric Skin Conditions
This is what I wanted to see. It's was the obvious question. If people were treated over a wide time span, where are they now and how is the skin holding up. This is the nice thing about the upcoming ESS trial. The company doesn't have to wait years to see the outcome.
Amarantus Reports Preliminary 13-Year Longitudinal Follow-Up Human Patient Data for Engineered Skin Substitute Treatment of Congenital Giant Hairy Nevus
http://ir.amarantus.com/press-releases/detail...ngitudinal
(0)
(0)
